Immune-system-based therapies as checkpoint inhibitors, immune-cell engagers, and engineered cell therapies have been invested to be the gamechanger in the field, especially in some subtypes of sAML (e.g., TP53 mutant AML). Here, TP53 is linked to acute myeloid leukemia.